RU1212045C - Protecting atmosphere for preparing dry virus vaccine - Google Patents

Description

 The invention relates to biotechnology and for the production of dry viral vaccines.

 The aim of the invention is to increase the shelf life of the immunogenicity of the target product.

 PRI me R 1. For the preparation of a protective environment using a protein hydrolyzate containing peptides,%: high molecular weight (30-80 thousand g) 10, medium molecular weight (5-30 thousand g) 65, low molecular weight (less than 5 thousand g ) 25.

Prepare a protective environment of the following composition, g:
Protein Hydrolyzate 15
Lactose 15
K ₂ HPO ₄ 0.52
KH ₂ PO ₄ 0.12
Distilled water Up to 100 g and the resulting medium are sterilized by filtration.

Virus-containing material representing the experimental series of Newcastle disease embryonic vaccine is mixed with a protective medium in a ratio of 3: 1. Prepared samples are packaged, frozen and dried. The biological activity of the virus in samples which are stored 12 months at 6-4 ^{° C,} varies by less than 1,2 lg EID _{50 / ml.}

PRI me R 2. For the preparation of a protective environment using a protein hydrolyzate containing peptides,%: high molecular weight 12.5; molecular weight 67.5; low molecular weight rest. Prepare a protective environment of the following composition, g:
Protein hydrolyzate 20
Lactose 20
K ₂ HPO ₄ 1.64
KH ₂ PO ₄ 0.24
Distilled Water Up to 100
The medium is sterilized by filtration, mixed with virus-containing material in a ratio of 1: 3, the resulting mixture is packaged, frozen and dried. As the virus-containing material, an experimental series of embryonic vaccines from the Boron strain 74 of the Newquel disease virus is used. During the 6 months of storage at ²⁰ ° C virus activity is reduced by no more than 3.6 lg EID _{50 / ml,} 12 months storage at ⁴ ° C - not more than 1 lg EID _{50 / ml.}

PRI me R 3. To prepare a protective environment using protein hydrolyzate containing peptides,%: high molecular weight 15, medium molecular weight 70, low molecular weight - the rest. Prepare a solution of the protective medium, take 25.0 g of protein hydrolyzate, 25.0 g of lactose, 2.76 g of K ₂ HPO ₄ , 0.36 g of KH ₂ PO ₄ , distilled water - the rest (up to 100.0), sterilized by filtration . An experimental series of culture vaccine against Marek’s disease is being prepared. The virus-containing material is mixed with a protective medium and sonicated. Prepared vaccine samples are packaged, frozen and dried. The stability of virus in the vaccine is checked largest infectivity titer reduction after storage of samples of vaccine dry for 1 month at 4-6 ° ^C.

 The titer of the virus during storage under these conditions practically does not change.

Example 4. A protective medium is used as described in Example 2. An experimental series of embryonic vaccine against smallpox of birds (New Jeren strain) is prepared as the viral material. The vaccine is mixed with a protective medium in a ratio of 3: 1, the mixture is packaged, lyophilized. At 12 months after storage at 4-6 ^{° C} virus activity practically unchanged.

Claims (1)

PROTECTIVE ENVIRONMENT FOR PREPARATION OF DRY VIRAL VACCINE, containing carbohydrate, K ₂ HPO ₄ , KH ₂ PO ₄ , a source of peptides and distilled water, characterized in that, in order to increase the shelf life of the immunogenicity of the target product, it contains lactose as a carbohydrate, and in as a source of peptides - protein hydrolyzate in the following quantitative ratio of components, wt.%
Protein hydrolyzate 15 - 25
Lactose 15 - 25
K ₂ HPO ₄ 0.52 - 2.76
KH ₂ PO ₄ 0.12 - 0.36
Distilled water Up to 100.0
wherein the protein hydrolyzate contains, wt.%:
High molecular weight peptides (30000 - 80000g) 10 - 15
Medium molecular peptides (5000 - 30000g) 65 - 70
Low molecular weight peptides (less than 5000g)